Evidence tier
Mixed
Research weight
Citations
19 verified / 19
Classification
Gut & Immune
❝
What the evidence says. Conflicting results across studies; benefit uncertain.
What is Probiotics?
Probiotics is a gut and immune supplement used for antibiotic-associated diarrhea. NutriDex grades the human evidence as Mixed. Probiotics are live microorganisms that can confer health benefits — but effects are highly strain- and condition-specific. The strongest evidence is for preventing antibiotic-associated and infectious diarrhea and easing some IBS symptoms. Generic 'gut health' or immunity claims are far weaker. Benefits rarely persist after stopping, and a strain proven for one use may do nothing for another.
Purported Benefits
✓Antibiotic-associated diarrhea
✓IBS symptoms
✓Gut balance
✓Some immune support
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Antibiotic-associated diarrhea preventionCochrane in children: 19%->8% (RR 0.45, moderate certainty); strain- and dose-dependent. | Strong | ↑ benefit · moderate | 3 |
| C. difficile-associated diarrhea preventionCochrane ~50% reduction but 2025/2026 updates downgrade certainty to low; benefit largest in high-risk patients. | Moderate | ↑ benefit · moderate | 3 |
| IBS global symptomsNetwork meta-analysis of 82 RCTs shows benefit but mostly low/very-low certainty; AGA only suggests use in trials. | Mixed | ↑ benefit · small | 2 |
| Acute infectious diarrheaUpdated Cochrane low-bias trials: little/no effect on diarrhea >=48h (RR 1.00); publication bias demonstrated. | Moderate | — no effect · negligible | 2 |
| Necrotizing enterocolitis in preterm infantsUmbrella meta-analysis ~halved NEC and reduced mortality; AGA conditionally recommends specific strains. | Moderate | ↑ benefit · large | 2 |
| Upper respiratory tract infectionsCochrane: fewer episodes and antibiotic use, but URTI incidence reduction is low-certainty. | Moderate | ↑ benefit · small | 1 |
| Depression/anxiety symptomsMeta-analysis in diagnosed patients shows large SMDs but high heterogeneity and an outlier-prone literature. | Preliminary | ↑ benefit · moderate | 1 |
Dosing & Compounds
Typical Dose
Strain-specific; commonly 1–10 billion CFU/day. Match strain to the studied condition.
Active Compounds
Safety & Cautions
Safe for most. Transient gas/bloating. Caution in immunocompromised or critically ill patients. Educational only — always check with your doctor or pharmacist before combining Probiotics with any medicine.
Key Studies ★ 19 studies
Cochrane review
Goldenberg/Cochrane 2025 (update)
✓ PubMed
Updated Cochrane review (38 trials, 13,179 participants) found probiotics reduce C. difficile-associated diarrhea by ~50% (RR 0.50, 95% CI 0.38-0.64; ~1 case prevented per 65 treated), low-certainty evidence.
Meta-analysis
Goodoory 2023 (Gastroenterology)
✓ PubMed
Network meta-analysis of 82 RCTs (10,332 IBS patients) found benefit for global symptoms with only low-to-very-low certainty for most strains (Escherichia strains moderate certainty).
Meta-analysis
Wang 2025 (BMC Gastroenterol)
✓ PubMed
Umbrella meta-analysis of 35 studies in preterm infants found probiotics roughly halved necrotizing enterocolitis (ESRR 0.51, 95% CI 0.46-0.55) and reduced mortality (ESRR 0.72, 95% CI 0.68-0.76).
Meta-analysis
Sharma 2025 (Nutrition Reviews)
✓ Full text
Meta-analysis in clinically diagnosed samples (23 RCTs, 1,401 patients) found probiotics reduced depression (SMD -0.96, 95% CI -1.31 to -0.61) and anxiety (SMD -0.59), while prebiotics showed no significant effect.
Meta-analysis
Sharif 2023 (Nutrition Reviews)
✓ PubMed
Systematic review/meta-analysis of RCTs in critically ill adults found probiotics reduced ICU-acquired infections (RR 0.73, 95% CI 0.58-0.93) with no mortality benefit and no probiotic-attributed adverse events.
meta-analysis
Chen 2025 (Ann Med)
✓ PubMed
Systematic review/meta-analysis of 12 RCTs (2,144 participants) found probiotics pretreatment improved H. pylori eradication rate (ITT 80.3% vs 70.5%, RR 1.14, 95% CI 1.08-1.19) and reduced treatment side effects (16.0% vs 28.3%, RR 0.59, 95% CI 0.41-0.84).
meta-analysis
Wang 2023 (Transl Pediatr)
✓ PubMed
Systematic review/meta-analysis of 37 RCTs (6,131 children) found probiotics modestly reduced incidence of atopic dermatitis versus placebo (RR 0.83, 95% CI 0.73-0.94), with greatest effect for maternal-infant Lactobacillus rhamnosus regimens.
Cochrane review
Collinson 2020 (Cochrane)
✓ Full text
Cochrane review of probiotics for acute infectious diarrhoea found little to no effect on diarrhoea lasting >=48 hours or stool volume, not supporting routine use given heterogeneity and bias.
meta-analysis
van der Schoot 2022 (Clin Nutr)
✓ PubMed
Systematic review/meta-analysis (30 probiotic RCTs) found probiotics increased treatment response in chronic constipation (57% vs 44%, RR 1.28, 95% CI 1.07-1.52) and stool frequency (SMD 0.71), driven by Bifidobacterium lactis, while synbiotics showed no benefit.
Systematic review
Zhao et al. 2022 (Cochrane)
✓ PubMed
Cochrane review of 24 RCTs (6,950 participants). Probiotics reduced participants with >=1 acute upper respiratory tract infection (RR 0.76, 95% CI 0.67-0.87; low-certainty), >=3 episodes (RR 0.59, 95% CI 0.38-0.91; moderate-certainty), mean episode duration (-1.22 days, 95% CI -2.12 to -0.33), and prescribed antibiotic use (RR 0.58, 95% CI 0.42-0.81; moderate-certainty).
Systematic review
Collinson et al. 2020 (Cochrane)
✓ PubMed
Updated Cochrane review of 82 RCTs (12,127 participants, mostly children). Contrary to earlier reviews, in low-risk-of-bias trials probiotics made little or no difference to risk of diarrhea lasting >=48 hours (RR 1.00, 95% CI 0.91-1.09; moderate-certainty) and effect on diarrhea duration was uncertain (MD -8.6 hours, 95% CI -29.4 to +12.1; very low-certainty). Publication bias was demonstrated.
Meta-analysis
Ford 2018 meta-analysis
✓ PubMed
Modest improvement in global IBS symptoms.
Cochrane review
Goldenberg 2017 (Cochrane)
✓ Full text
S. boulardii / Lactobacillus prevented C. difficile diarrhea.
Cochrane review
Guo 2019 (Cochrane, pediatric AAD)
✓ PubMed
In children, probiotics reduced antibiotic-associated diarrhea from 19% (598/3120) to 8% (259/3232) (RR 0.45, 95% CI 0.36-0.56; 6352 participants; NNTB 9; moderate-certainty evidence), with high-dose probiotics most effective (RR 0.37, 95% CI 0.30-0.46).
Meta-analysis
Goldenberg et al. 2017 (Cochrane)
✓ PubMed
Cochrane review of 39 RCTs (9,955 participants). Among 31 trials (8,672 patients), probiotics co-administered with antibiotics reduced C. difficile-associated diarrhea by ~60% (1.5% vs 4.0%; RR 0.40, 95% CI 0.30-0.52; moderate-certainty; NNT 42). In high-baseline-risk patients (>5%) the reduction was ~70% (RR 0.30, 95% CI 0.21-0.42; NNT 12). No reduction in C. difficile stool infection rates (RR 0.86, 95% CI 0.67-1.10).
Guideline
Su 2020 (AGA guideline)
✓ Source
AGA clinical practice guideline conditionally recommends specific probiotics for only 3 of 8 GI uses (C. difficile prevention, pouchitis, NEC in preterm infants) and recommends against use for acute gastroenteritis in children.
Guideline
Su et al. 2020 (AGA Guideline)
✓ PubMed
American Gastroenterological Association clinical practice guideline. Conditionally recommends specific probiotics only for: prevention of C. difficile infection in adults/children on antibiotics, prevention of necrotizing enterocolitis in preterm low-birth-weight infants, and pouchitis. Recommends AGAINST probiotics for routine acute infectious gastroenteritis in children and suggests probiotics only in research/trial context for IBS, Crohn's, and ulcerative colitis given insufficient evidence.
Review
Chen 2026 (Frontiers in Nutrition)
✓ Source
Umbrella review of 16 systematic reviews on probiotics for C. difficile infection prevention rated 11 reviews as critically low confidence (AMSTAR-2) and graded overall certainty of efficacy evidence as low under GRADE.
Study
Hempel 2012 (JAMA)
✓ PubMed
Reduced antibiotic-associated diarrhea risk ~42%.